Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Bruno Bezerra Lima

Advanced Cardiac Imaging · VUMC

View

Dr. Sara Ersozlu

Advanced Cardiac Imaging · MGH

View

Dr. Christopher Kramer

Advanced Cardiac Imaging · University of Virginia

View

Dr. Filipe Moura

Advanced Cardiac Imaging · Yale College

View

Dr. Robert Hendel

Advanced Cardiac Imaging · Tulane University

View

Dr. Venkatesh Murthy

Advanced Cardiac Imaging · UMHS

View

Dr. Dorairaj Prabhakaran

General Cardiology

View

Dr. Pugazhendhi Vijayaraman

EP · Geisinger

View

Dr. Robert Schaller

EP · HUP

View

Dr. Trey Woods

General Cardiology · Emory Healthcare

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Elevated Lipoprotein(a) With Zero Coronary Artery Calcium: A Silent Threat or a Clinical Paradox?

    Jul 16, 2024DOI: 10.1161/circimaging.124.017136EditorialAHA

    Written by: Patricia F Rodriguez LozanoNisha Hosadurg

    Find these authors on Roon

    PR
    Dr. Patricia Rodriguez Lozano
    Advanced Cardiac Imaging · University of Virginia

    FUTURE DIRECTIONS

    The provocative findings from this study open several avenues for future research. First, there is a need for larger, multicenter, prospective studies that can validate the association of Lp(a) with specific plaque characteristics using more precise and quantitative imaging techniques. Investigating the longitudinal impact of elevated Lp(a) on plaque progression and ASCVD events, particularly focusing on the role of noncalcified plaque, will provide crucial insights.Second, exploring the interplay between Lp(a), inflammation, and coronary microvascular disease (CMD) can uncover novel mechanisms and therapeutic targets. CMD, often underdiagnosed, poses significant cardiovascular risks, and understanding its relationship with Lp(a) could lead to better risk stratification and management, especially in women who are disproportionately affected.Additionally, role of other CCTA-based novel radiomics should be explored, like the role of pericoronary adipose tissue (PCAT) as a marker of inflammation in relation to elevated Lp(a) warrants further exploration. Advanced imaging techniques assessing PCAT could enhance our understanding of the inflammatory milieu associated with high Lp(a) levels and its contribution to ASCVD risk.Last, the development and evaluation of Lp(a)-lowering therapies should be closely monitored using advanced imaging modalities like CCTA to assess their impact on plaque stabilization and regression. Such studies could pave the way for personalized treatment approaches that consider both traditional risk factors and novel markers like Lp(a).The intriguing and sometimes paradoxical findings of this study underscore the complexity of cardiovascular risk assessment and the need for continued innovation in both diagnostic and therapeutic strategies. As our understanding of Lp(a) evolves, so too must our approach to managing the risks it presents.
    PRDr. Patricia Rodriguez Lozano

    Dr. Patricia Rodriguez Lozano

    Cardiology · Advanced Cardiac Imaging
    University of Virginia Health System
    patricia
    Charlottesville, VA, USA